Inhibikase Therapeutics (IKT) Income from Continuing Operations (2020 - 2026)
Inhibikase Therapeutics' (IKT) quarterly Income from Continuing Operations came in at 17841919.0 in Q1 2026, down 22.21% year-on-year from 22934810.62 in Q1 2025, and up 16.92% on a QoQ basis from 21475626.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Income from Continuing Operations data on file, last reported at 17841919.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 22.21% year-over-year to 17841919.0 in Q1 2026; TTM through Mar 2026 was 62956518.0, a 62.47% decrease from a year earlier, with the FY2025 full-year figure at 83633124.0, down 40.11% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 17841919.0, up from 21475626.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for IKT reached as high as 4334974.0 in Q4 2022 and fell as low as 21475626.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 8523605.41 across 5 years, with a median of 5241081.0 in 2024.
- Across the five-year window, Income from Continuing Operations grew 16.05% in 2024 and tumbled 204.12% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 4334974.0 in 2022, then retreated by 1.58% to 4403566.0 in 2023, then slumped by 193.6% to 12928700.0 in 2024, then tumbled by 66.11% to 21475626.0 in 2025, then advanced by 16.92% to 17841919.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 17841919.0 in Q1 2026, 21475626.0 in Q4 2025, and 12768373.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - | -17.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.84 Mn |
| Dec 31, 2025 | -21.48 Mn |
| Sep 30, 2025 | -12.77 Mn |
| Jun 30, 2025 | -10.87 Mn |
| Mar 31, 2025 | -14.60 Mn |
| Dec 31, 2024 | -12.93 Mn |
| Sep 30, 2024 | -5.98 Mn |
| Jun 30, 2024 | -5.24 Mn |
| Mar 31, 2024 | -4.80 Mn |
| Dec 31, 2023 | -4.40 Mn |
| Sep 30, 2023 | -4.80 Mn |
| Jun 30, 2023 | -6.24 Mn |
| Mar 31, 2023 | -4.76 Mn |
| Dec 31, 2022 | -4.33 Mn |
| Sep 30, 2022 | -4.56 Mn |
| Jun 30, 2022 | -4.64 Mn |
| Mar 31, 2022 | -4.64 Mn |
| Dec 31, 2021 | -5.02 Mn |
| Sep 30, 2021 | -4.47 Mn |
| Jun 30, 2021 | -2.64 Mn |